MA38245B1 - Novel heterocyclic compounds and their compositions for the prevention and treatment of diseases such as epilepsy and alzheimer - Google Patents
Novel heterocyclic compounds and their compositions for the prevention and treatment of diseases such as epilepsy and alzheimerInfo
- Publication number
- MA38245B1 MA38245B1 MA38245A MA38245A MA38245B1 MA 38245 B1 MA38245 B1 MA 38245B1 MA 38245 A MA38245 A MA 38245A MA 38245 A MA38245 A MA 38245A MA 38245 B1 MA38245 B1 MA 38245B1
- Authority
- MA
- Morocco
- Prior art keywords
- epilepsy
- prevention
- treatment
- alzheimer
- diseases
- Prior art date
Links
- 206010015037 epilepsy Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention a pour objet de produire un composé ou un sel de celui-ci qui est utile comme agent pour la prévention ou le traitement de l'épilepsie, de maladie neurodégénérative et similaire. L'invention concerne des composés représentés par la formule (i) (dans la formule, chaque symbole est tel que défini dans la description) ou des sels de ceux-ci.It is an object of the present invention to provide a compound or a salt thereof which is useful as an agent for the prevention or treatment of epilepsy, neurodegenerative disease and the like. The invention relates to compounds represented by the formula (i) (in the formula, each symbol is as defined in the description) or salts thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012270445 | 2012-12-11 | ||
| PCT/JP2013/083140 WO2014092100A1 (en) | 2012-12-11 | 2013-12-10 | Heterocyclic compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38245A1 MA38245A1 (en) | 2017-01-31 |
| MA38245B1 true MA38245B1 (en) | 2017-09-29 |
Family
ID=58795928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38245A MA38245B1 (en) | 2012-12-11 | 2013-12-10 | Novel heterocyclic compounds and their compositions for the prevention and treatment of diseases such as epilepsy and alzheimer |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA38245B1 (en) |
-
2013
- 2013-12-10 MA MA38245A patent/MA38245B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA38245A1 (en) | 2017-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40955A (en) | 2-AMINO-6- (DIFLUOROMETHYL) -5,5-DIFLUORO-6-PHENYL-3,4,5,6-TETRAHYDROPYRIDINES AS BACE1 INHIBITORS | |
| MA44721B1 (en) | Macrocyclic mcl1 inhibitors for cancer treatment | |
| MA43169B1 (en) | Heterocyclic compounds as pi3k-gamma inhibitors | |
| MA48577A1 (en) | Biheteroaryl compounds and their uses | |
| EA201890338A1 (en) | OXADIAZOLIC DERIVATIVES SUITABLE AS HDAC INHIBITORS | |
| MA39152A1 (en) | 1,2-substituted cyclopentanes used as orexin receptor antagonists | |
| MA37866B1 (en) | Aza-indazole or diaza-indazole derivatives for the treatment of pain | |
| MA34903B1 (en) | AZAINDAZOLE OR DIAZAINDAZOLE DERIVATIVES AS MEDICAMENTS | |
| MA35285B1 (en) | indazoles | |
| EA201201665A1 (en) | NEW CONNECTIONS | |
| MA34837B1 (en) | INDOLIC COMPOUNDS OR ANALOGS THEREFOR USEFUL IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | |
| MA39225A1 (en) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines used as bace1 inhibitors in the treatment of alzheimer's disease | |
| TN2015000347A1 (en) | AZABENZIMIDAZOLES AS INHIBITORS OF PDE4 ISOENZYMES FOR THE TREATMENT OF CNS DISORDERS AND OTHER DISORDERS | |
| MA47736B1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SA520411783B1 (en) | Condensed imidazole derivatives with tertiary hydroxy substitution as PI3K-gamma inhibitors | |
| MA39170A1 (en) | Serine / threonine kinase inhibitory compounds for their uses in the treatment of cancer | |
| PH12013500644A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| MA39983B1 (en) | Carboxamide derivatives | |
| MA37765A1 (en) | Substituted pyrazole compounds used as lpar antagonists | |
| MA37501B1 (en) | Pyrazole compounds used as sglt1 inhibitors | |
| MA38410A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| MA38250B1 (en) | New hydantoin derivatives for their uses in the treatment of diseases, such as osteoporosis and thrombocytopenia | |
| MD20190080A2 (en) | Crystalline forms of (s) -afoxolaner | |
| MA39253B1 (en) | Substituted bicyclic heteroaryl compounds used as rxr agonists | |
| MA38307A1 (en) | 4-hydroxy-2-methyl-5- (propan-2-ylidene) cyclohex-3-enecarbaldehyde for the prevention and treatment of cognitive, neurodegenerative or neuronal disease |